Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asundexian versus apixaban for stroke prevention in atrial fibrillation
NL-OMON53820Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Asundexian with Apixaban (2 arms). Primary endpoints: Composite of stroke or systemic embolism and ISTH major bleeding. Started Jan 2023; status: active, not recruiting.
02
Drugs
asundexianapixaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON53820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53820.